- Home
- GNTA vs PSNL Comparison
GNTA vs PSNL Comparison
Compare GNTA & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNTA | PSNL |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | Italy | United States |
| Employees | 13 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.9M | 729.1M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | GNTA | PSNL |
|---|---|---|
| Price | $0.78 | $7.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $12.20 |
| AVG Volume (30 Days) | 54.1K | ★ 1.4M |
| Earning Date | 03-24-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.58 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $69,648,000.00 |
| Revenue This Year | N/A | $15.47 |
| Revenue Next Year | N/A | $39.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.59 | $2.83 |
| 52 Week High | $10.00 | $11.50 |
Technical Indicators
Market Signals| Indicator | GNTA | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 38.00 | 49.80 |
| Support Level | $0.71 | $7.74 |
| Resistance Level | $1.70 | $9.64 |
| Average True Range (ATR) | 0.09 | 0.52 |
| MACD | -0.01 | 0.07 |
| Stochastic Oscillator | 40.91 | 70.21 |
Price Performance
Historical ComparisonAbout GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.